Literature DB >> 21263266

Evaluation of treatment response after nonoperative therapy for early-stage non-small cell lung carcinoma.

Jilbert Eradat1, Fereidoun Abtin, Antonio Gutierrez, Robert Suh.   

Abstract

Nonsurgical management of early primary lung cancer has grown tremendously in recent years, and today, available options extend far beyond that of conventional radiation therapy (CRT) to include minimally invasive image-guided delivery of thermal energies, specifically radiofrequency ablation, microwave ablation, and cryoablation, and more conformal stereotactic body radiation therapy. Because the tumor is never resected with these nonoperative interventions, histopathological evaluation of tumor margins for the presence of residual tumor is impossible, and as such, tumor response after each of these therapies is largely based on imaging. To date, computerized tomography and computerized tomography-positron emission tomography remain the most readily available modalities for assessment of therapeutic efficacy, and to this end as detailed within this article, strict imaging survey and familiarity with the expected imaging characteristics of the treated tumor will aid in recognition of unexpected findings, specifically those of incomplete therapy and/or tumor recurrence.

Entities:  

Mesh:

Year:  2011        PMID: 21263266     DOI: 10.1097/PPO.0b013e31820a0948

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  9 in total

Review 1.  Post-therapeutic positron emission tomography/computed tomography for early detection of non-small cell lung cancer recurrence.

Authors:  Sonja Sudarski; Thomas Henzler; Stefan O Schoenberg
Journal:  Transl Lung Cancer Res       Date:  2013-08

Review 2.  Surgery versus stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer: less is not more.

Authors:  Abby White; Scott J Swanson
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

3.  Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases.

Authors:  Xia Yang; Xin Ye; Aimin Zheng; Guanghui Huang; Xiang Ni; Jiao Wang; Xiaoying Han; Wenhong Li; Zhigang Wei
Journal:  J Surg Oncol       Date:  2014-06-25       Impact factor: 3.454

4.  Study of survival in patients with malignant lung lesions treated with radiofrequency.

Authors:  J M Galbis Caravajal; J Jornet Fayos; M Cuenca Torres; E Mollá Olmos; M Estors Guerrero; F Sánchez García; N J Martinez Hernandez; R Esturi Navarro; A Pastor del Campo; M Vaño Molina
Journal:  Clin Transl Oncol       Date:  2013-03-22       Impact factor: 3.405

Review 5.  Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria.

Authors:  Andrea Caulo; Saeed Mirsadraee; Fabio Maggi; Lucia Leccisotti; Edwin J R van Beek; Lorenzo Bonomo
Journal:  Eur Radiol       Date:  2011-10-04       Impact factor: 5.315

6.  Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer.

Authors:  Yoshikane Yamauchi; Yotaro Izumi; Kohei Hashimoto; Hideki Yashiro; Masanori Inoue; Seishi Nakatsuka; Taichiro Goto; Masaki Anraku; Takashi Ohtsuka; Mitsutomo Kohno; Masafumi Kawamura; Hiroaki Nomori
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

Review 7.  More than just tumor destruction: immunomodulation by thermal ablation of cancer.

Authors:  Sebastian P Haen; Philippe L Pereira; Helmut R Salih; Hans-Georg Rammensee; Cécile Gouttefangeas
Journal:  Clin Dev Immunol       Date:  2011-12-29

8.  Long-term outcome following microwave ablation of lung metastases from colorectal cancer.

Authors:  Yue Han; Xue Yan; Weihua Zhi; Ye Liu; Fei Xu; Dong Yan
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

9.  CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases.

Authors:  Qiang Lu; Wei Cao; Lijun Huang; Yi Wan; Tonggang Liu; Qingshu Cheng; Yong Han; Xiaofei Li
Journal:  World J Surg Oncol       Date:  2012-05-07       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.